Molecular Partners AG (MOLN)
NASDAQ: MOLN · IEX Real-Time Price · USD
4.200
+0.290 (7.42%)
At close: Mar 27, 2024, 12:00 AM
4.135
-0.065 (-1.55%)
After-hours: Mar 28, 2024, 4:20 PM EDT
Molecular Partners AG Market Cap
Molecular Partners AG has a market cap or net worth of $132.73 million as of March 28, 2024. Its market cap has decreased by -29.73% in one year.
Market Cap
132.73M
Enterprise Value
-70.47M
1-Year Change
-29.73%
Ranking
Category
Stock Price
$4.20
Market Cap Chart
Since the IPO on June 16, 2021, Molecular Partners AG's market cap has decreased from $683.35M to $132.73M, a decrease of -80.58%. That is a compound annual growth rate of -44.50%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 28, 2024 | 138.00M | - |
Mar 27, 2024 | 138.00M | -0.93% |
Mar 26, 2024 | 139.30M | 1.46% |
Mar 25, 2024 | 137.30M | 2.77% |
Mar 22, 2024 | 133.60M | 4.78% |
Mar 21, 2024 | 127.50M | - |
Mar 20, 2024 | 127.50M | 0.31% |
Mar 19, 2024 | 127.10M | -7.56% |
Mar 18, 2024 | 137.50M | 5.69% |
Mar 15, 2024 | 130.10M | 2.44% |
Mar 14, 2024 | 127.00M | 3.67% |
Mar 13, 2024 | 122.50M | -6.63% |
Mar 12, 2024 | 131.20M | -2.89% |
Mar 11, 2024 | 135.10M | -1.31% |
Mar 8, 2024 | 136.90M | -1.65% |
Mar 7, 2024 | 139.20M | 0.94% |
Mar 6, 2024 | 137.90M | 2.91% |
Mar 5, 2024 | 134.00M | -2.05% |
Mar 4, 2024 | 136.80M | 0.15% |
Mar 1, 2024 | 136.60M | -3.26% |
Feb 29, 2024 | 141.20M | - |
Feb 28, 2024 | 141.20M | -4.85% |
Feb 27, 2024 | 148.40M | -2.37% |
Feb 26, 2024 | 152.00M | 15.41% |
Feb 23, 2024 | 131.70M | -8.86% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
aTyr Pharma | 136.79M |
MediWound | 136.68M |
NGM Biopharmaceuticals | 135.21M |
Emergent BioSolutions | 135.21M |
YS Biopharma Co. | 133.71M |
Annovis Bio | 132.47M |
Sangamo Therapeutics | 127.23M |
Genetron Holdings | 127.13M |